Keane Lily, Cheray Mathilde, Blomgren Klas, Joseph Bertrand
Institute of Environmental Medicine, Toxicology Unit, Karolinska Institutet, Stockholm, Sweden.
Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
Nat Rev Neurol. 2021 Apr;17(4):243-259. doi: 10.1038/s41582-021-00463-2. Epub 2021 Mar 10.
Microglia are the resident innate immune cells of the immune-privileged CNS and, as such, represent the first line of defence against tissue injury and infection. Given their location, microglia are undoubtedly the first immune cells to encounter a developing primary brain tumour. Our knowledge of these cells is therefore important to consider in the context of such neoplasms. As the heterogeneous nature of the most aggressive primary brain tumours is thought to underlie their poor prognosis, this Review places a special emphasis on the heterogeneity of the tumour-associated microglia and macrophage populations present in primary brain tumours. Where available, specific information on microglial heterogeneity in various types and subtypes of brain tumour is included. Emerging evidence that highlights the importance of considering the heterogeneity of both the tumour and of microglial populations in providing improved treatment outcomes for patients is also discussed.
小胶质细胞是免疫特权中枢神经系统中的常驻固有免疫细胞，因此是抵御组织损伤和感染的第一道防线。鉴于其所处位置，小胶质细胞无疑是最早接触原发性脑肿瘤发生发展的免疫细胞。因此，在这类肿瘤的背景下考虑我们对这些细胞的认识很重要。由于最具侵袭性的原发性脑肿瘤的异质性被认为是其预后不良的基础，本综述特别强调原发性脑肿瘤中肿瘤相关小胶质细胞和巨噬细胞群体的异质性。在可行的情况下，还纳入了关于各种类型和亚型脑肿瘤中小胶质细胞异质性的具体信息。本文还讨论了新出现的证据，这些证据强调了考虑肿瘤和小胶质细胞群体的异质性对于改善患者治疗效果的重要性。
